The United States Agency for International Development (USAID) Bureau for Democracy, Conflict, and Humanitarian Assistance Office of U.S. Foreign Disaster Assistance (DCHA/OFDA) requested Food and Nutrition Technical Assistance II Project (FANTA-2) assistance to review Community-Based Management of ...Acute Malnutrition (CMAM) in four West African countries—Burkina Faso, Mali, Mauritania, and Niger—to help identify DCHA/OFDA 2010 and 2011 program priorities, including where DCHA/OFDA investment should be directed to support CMAM. The goal was to review CMAM program implementation and its integration into national health systems to provide DCHA/OFDA a status report for each country; draw lessons learned; and make recommendations on challenges, promising practices, gaps, and priority areas for DCHA/OFDA support during 2010 and 2011. The review was intended for DCHA/OFDA program planning purposes and also potentially as an advocacy tool to guide other donors in planning CMAM support in the region. After all four countries have been reviewed, FANTA-2 will develop a synthesis report. The current document presents a summary report on CMAM in Burkina Faso only.
more
Au Burkina Faso, les personnes vivant avec le VIH (PvVIH) ont régulièrement recours à des substances naturelles pour traiter certaines infections opportunistes. C’est ainsi que le suc des feuilles fraîches de Mitracarpus scaber Zucc. ex Schult. & Schult. f. (Rubiaceae) et de Senna alata (L.) R...oxb. (Fabaceae) sont utilisés comme antimycosiques. En ce qui concerne le zona et les poussées herpétiques, les feuilles fraîches de Phyllanthus amarus Schumach. & Thonn. (Euphorbiaceae), la sève de Mangifera indica L. (Anacardiaceae), le gel de Aloe buettneri Berger (Liliaceae) et la galle de Guiera senegalensis J.F. Gmel. (Combretaceae), sont les drogues végétales les plus utilisées. Des substances naturelles sont également recommandées par les tradipraticiens de santé pour la récupération immunologique et nutritionnelle, le traitement précoce de l’infection à VIH et la réduction des effets secondaires des traitements ARV (antirétroviral). Il s’agit respectivement pour les plus importantes d’entre elles, des feuilles de Moringa oleifera Lam. (Moringaceae), de la pulpe du fruit de Detarium microcarpum Guill. & Perr. (Fabaceae), de la spiruline et du pollen issu de la ruche.
Les substances naturelles pouvant avoir une interaction avec les traitements conventionnels et plus particulièrement avec les médicaments ARV, les plantes contenant des tanins catéchiques, des dérivés 1,8 hydroxyanthracéniques laxatifs et des molécules hépatotropes ou inductrices enzymatiques, sont classées à risque, et leur utilisation par les PvVIH est étroitement surveillée.
more
Lignes directrices provisoires, 13 août 2020
L’OMS a établi cette brève note d’information pour répondre au besoin de recommandations sur la prestation sûre de soins à domicile aux patients présumés atteints de l’infection par le nouveau coronavirus (2019-nCoV) présentant des symptô...mes bénins, et sur les mesures de santé publique liées à la prise en charge des contacts asymptomatiques.
more
Accessed on 20.10.2020
In its fight against maternal mortality, the government of Burkina Faso is supported
by the donor community which contributes to the health budget and also supports
specific projects aimed at improving access to health care. This report acknowledges
the efforts to address ...maternal mortality undertaken by the government with the help
of the donor community, as well as projects led by international and national NGOs.
more
La méningite est mortelle et débilitante ; elle frappe brutalement ; elle a de graves conséquences sanitaires, économiques et sociales et touche tous les âges de la vie dans tous les pays du monde. La méningite bactérienne peut être à l’origine d’épidémies, entraîner la mort dans les... 24 heures et un patient sur cinq peut rester handicapé à vie à la suite d’une infection. La plupart des cas et des décès dus à la méningite pourraient être évités par la vaccination mais les progrès obtenus pour la vaincre sont bien moins rapides que ceux réalisés contre d’autres maladies à prévention vaccinale.
more
This policy brief aims to provide a review of the current progress on implementing the Burkina Faso national action plan on AMR, identifies critical gaps, and highlights findings to accelerate further progress in the human health sector. The target audience includes all those concerned with implemen...ting actions to combat antimicrobial resistance in Burkina Faso.
more
This manual is addressed to health care providers dealing with Mycobacterium ulcerans disease (Buruli ulcer). The manual aims to achieve a better understanding of the disease, its clinical presentation and its surgical management. The manual is aimed particularly at district health care providers. A... comprehensive protocol, adapted to each form and stage of the disease, is presented together with comments on the levels of resources and capabilities necessary
to shorten the length of treatment, to prevent complications and to minimize undesired sequelae and thus to obtain the best possible outcome for each patient. Some sections include advice relevant to surgeons (e.g. relating to bone infection). However, the level to which particular comments are intended to apply should be clear from the context.
more
O presente documento destina-se afornecer orientações provisórias para a definição de casos de GBSe estratégias para gerir a síndrome, no contexto do vírus Zikae sua potencial associação com a GBS. Odocumento pretende informar a elaboração de protocolos clínicos locais e de políticas d...e saúde relacionadas com os cuidados a dispensar aos doentes com GBS. Em Março de 2016, será organizada uma reunião de peritos para elaborar outras orientações destinadas a identificar e gerir a GBS e outros possíveis distúrbios neurológicos,no contexto da transmissão do vírus Zika.
more
Esta é a primeira edição de orientações sobre estratégias de prevenção e controle de infecção (PCI) para utilizar quando houver suspeita de infecção por um novo coronavírus (2019-nCoV). Foi adaptado do guia da OMS de Prevenção e controle de infecções durante os cuidados de saúde pa...ra casos prováveis ou confirmados da infecção pelo coronavírus que causa a síndrome respiratória do Oriente Médio (MERS--CoV)1, com base no conhecimento atual da situação na China e em outros países onde foram identificados casos e experiências com a síndrome respiratória aguda grave (SARS)-CoV e MERS-CoV. A OMS atualizará essas recomendações assim que novas informações estiverem disponíveis. Esta orientação destina-se a profissionais de saúde, gerentes de saúde e equipes de PCI na atenção básica em saúde, mas também é relevante para os níveis nacional e subnacional. Diretrizes completas estão disponíveis na OMS.
more
Esta é a primeira edição da orientação sobre estratégias de prevenção e controle de infecções (PCI) que devem ser aplicadas quando houver suspeita de COVID-19. Ela foi adaptada do documento da OMS sobre prevenção e controle de infecções durante prestação de cuidados de saúde para ca...sos prováveis ou confirmados de infecção da síndrome respiratória do Oriente Médio (MERS-CoV)1, com base no conhecimento atual da situação e experiência com a síndrome respiratória aguda grave (SARS) e MERS2. A OMS atualizará estas recomendações à medida que novas informações forem surgindo. Esta orientação é dirigida a trabalhadores da saúde, administradores em saúde e equipes de PCI nas unidades de saúde, mas também é relevante para os níveis nacionais, estaduais e municipais.
more
Critical preparedness, readiness and response actions for COVID-19
Interim Guidance - 27 May 2021
Interim rapid response guidance, 10 June 2022.
It includes considerations for certain populations such as patients with mild disease with considerations for community care, patients with moderate to severe disease, sexually active persons, pregnant or breastfeeding women, children and young persons.... The guidance also addresses considerations for clinical management such as the use of therapeutics, nutritional support, mental health services, and post-infection follow-up.
The document provides guidance for clinicians, health facility managers, health workers and infection prevention and control practitioners including but not limited to those working in primary care clinics, sexual health clinics, emergency departments, infectious diseases clinics, genitourinary clinics, dermatology clinics, maternity services, paediatrics, obstetrics and gynaecology and acute care facilities that provide care for patients with suspected or confirmed monkeypox
more
Évaluation des mesures mises en oeuvre en cas de flambées et amélioration de la préparation
Guide d’urgence provisoire